Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence

Michele R. Schaeffer, Yannick Molgat-Seon, Christopher J. Ryerson, Jordan A. Guenette
European Respiratory Review 2017 26: 170033; DOI: 10.1183/16000617.0033-2017
Michele R. Schaeffer
1Centre for Heart Lung Innovation, Providence Health Care Research Institute, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada
2Dept of Physical Therapy, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yannick Molgat-Seon
1Centre for Heart Lung Innovation, Providence Health Care Research Institute, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada
3School of Kinesiology, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Ryerson
1Centre for Heart Lung Innovation, Providence Health Care Research Institute, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada
4Dept of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordan A. Guenette
1Centre for Heart Lung Innovation, Providence Health Care Research Institute, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada
2Dept of Physical Therapy, University of British Columbia, Vancouver, BC, Canada
3School of Kinesiology, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jordan.guenette@hli.ubc.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Previous methodological flaws led to erroneous conclusions on the effects of oxygen on exertional dyspnoea in ILD http://ow.ly/Y48d30dCMk9

To the Editor:

It is with great interest that we read the recent systematic review by Bell et al. [1] concerning the effects of oxygen therapy on dyspnoea and exercise capacity in patients with interstitial lung disease (ILD). The authors report that, while supplemental oxygen increases exercise capacity, it does not improve dyspnoea. Overall, this is a well-executed systematic review that accurately reflects the current literature; however, we believe the conclusion regarding the lack of benefit of supplemental oxygen on dyspnoea in ILD is misleading. This opinion is not based on the quality of the systematic review, but rather on the quality of the existing literature that was evaluated. We base our opinion on two important lines of evidence. First, previous studies that have evaluated the effect of supplemental oxygen on exertional dyspnoea in ILD patients only report peak or end-exercise dyspnoea ratings, thereby ignoring important clinically and physiologically relevant changes occurring at submaximal exercise intensities. Secondly, the exercise testing modalities employed are variable, such as self-paced walk tests [2–5] or incremental cycle exercise tests [6], which are often insensitive to changes in dyspnoea. An additional concern relates to the measures in place to reduce experimental bias, as the authors have addressed. Indeed, the only study included in their review that showed a beneficial effect of oxygen on dyspnoea did not have an appropriate control condition [5], making it impossible to rule out the placebo effect.

The measurement of dyspnoea is founded on the principle of psychophysics, whereby a stimulus is linked to a sensation [7]. It has been established that humans can reliably detect, quantify and discriminate qualitatively distinct sensations of dyspnoea provoked by different respiratory stimuli, either applied experimentally or as a result of disease [8]. Accordingly, the only way to properly evaluate the effects of any therapeutic intervention on exertional dyspnoea is to standardise the stimulus intensity. Specifically, this requires the assessment of dyspnoea at the same absolute exercise intensity and measurement time. It is extremely challenging to standardise exercise intensity during self-paced walk tests and thus, cycle exercise tests are more appropriate by design. Additionally, peak or end-exercise dyspnoea ratings are often insensitive to change following an intervention. This may be attributed to exercise tolerance improving as a result of the intervention and/or the fact that symptom-limited exercise cessation typically occurs at a similar level of dyspnoea for a given individual [9]. In other words, peak exercise is not the same stimulus if exercise time is increased (i.e. for incremental and constant work-rate cycle exercise tests) or if walking pace and/or distance changes (i.e. during self-paced walking tests).

In addition to standardising exercise intensity and measurement times, the magnitude of inspiratory oxygen fraction (FIO2) delivered should be the same between individuals and should be of sufficient magnitude to reverse or, at the very least, cause a meaningful improvement in arterial oxygen saturation. With the exception of one study [6], all previous studies that examined dyspnoea in ILD used nasal cannulae or venturi masks to deliver the oxygen at various flow rates [2–5, 10]. These gas delivery methods have well-established limitations [11, 12] and the effective FIO2 is likely to vary between individuals based on breathing pattern. These systems also have modest effects on improving arterial oxygen saturation compared with control conditions [2–5], which may explain, at least in part, previous negative studies of oxygen on dyspnoea in ILD. By contrast, administering oxygen through a reservoir bag connected to a two-way non-rebreathing valve, while less practical, allows for the precise control of FIO2 and is more effective at preventing arterial oxygen desaturation. This design is critical for testing the potential benefit of increased FIO2 on dyspnoea. If a benefit of supplemental oxygen during exercise is proven, there will be a need for additional research to identify the best means of translating these findings into clinical practice within a standard pulmonary rehabilitation setting. Thus, in order to make an unbiased evaluation of supplemental oxygen on dyspnoea, dyspnoea ratings should be measured at the same absolute submaximal work rate and exercise time (i.e. iso-time) while administering identical levels of effective FIO2 compared with an appropriate placebo condition.

We recently completed a study that addresses the aforementioned limitations in order to evaluate the effect of supplemental oxygen on dyspnoea during exercise in patients with ILD [13]. During this single-blind, randomised, placebo-controlled crossover study, 20 ILD patients performed two symptom-limited constant work-rate cycle exercise tests at 75% of peak work rate while breathing room air or supplemental oxygen (60% oxygen) in randomised order. Gas was delivered via a two-way non-rebreathing valve connected to a Douglas bag, such that the effective FIO2 was constant in all patients and was sufficient to reverse arterial oxygen desaturation, even at peak exercise (mean±sd arterial oxygen saturation measured by pulse oximetry was 98±1% with hyperoxia versus 90±4% with normoxia; p<0.001). Gas cylinders and oxygen saturation monitors were obstructed from patient view, and gas delivery was identical for both experimental conditions. Briefly, dyspnoea was significantly reduced at iso-time with supplemental oxygen versus room air (mean±sd 2.5±2.1 versus 4.4±3.1 Borg units; p<0.01), but was not different at peak exercise (5.4±3.6 versus 5.6±3.0 Borg units; p=0.69) despite a significant improvement in exercise endurance time by an average of 10.3 min (mean±sd 21.9±12.9 versus 11.6±10.0 min; p<0.001). Figure 1 shows mean data as well as the dyspnoea response from an individual patient to illustrate the fundamental importance of measuring and reporting submaximal dyspnoea ratings. The data clearly show a substantial and clinically relevant reduction in dyspnoea at iso-time with hyperoxia in both examples, with no improvement at peak exercise. Relying exclusively on peak dyspnoea, as has been done in previous studies, results in the erroneous conclusion that supplemental oxygen is ineffective at reducing dyspnoea. The results of our study clearly demonstrate a reduction in dyspnoea with supplemental oxygen by an amount that well exceeds the minimal clinically important difference (derived from chronic obstructive pulmonary disease studies) of 1 Borg unit (scale of 0–10) [14]. The positive results from this study formed the impetus for a large multicentre clinical trial evaluating the role of hyperoxia in a long-term exercise-training programme in patients with idiopathic pulmonary fibrosis [15].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Dyspnoea response at rest, iso-time, and peak exercise in 20 patients with fibrotic interstitial lung disease during constant work-rate cycle exercise testing while breathing 60% oxygen or room air. There was a statistically significant improvement in dyspnoea at iso-time but no change at peak exercise. Data are presented as mean±sem. *: p<0.05. b) Dyspnoea ratings every 2 min during constant load cycling in an individual patient while breathing 60% oxygen or room air. Dyspnoea ratings were reduced at all submaximal exercise times but the rating was increased at peak exercise. The Borg dyspnoea scale ranges from 0 to 10. Data from [13].

The comprehensive systematic review by Bell et al. [1] did not identify a clinically significant benefit of supplemental oxygen on dyspnoea in patients with ILD; however, this review is subject to the methodological limitations of the available literature. We believe that the primary conclusion to be drawn from the existing literature is that there is currently insufficient evidence to suggest either a benefit or a lack of benefit from supplemental oxygen during exercise in patients with ILD. Methodological factors, such as the mode of gas delivery, FIO2, the timing of dyspnoea measurements, and the exercise testing protocols, have been inadequately considered in most previous studies and probably contribute to the difference in conclusions between our study and the available literature. Before clinicians dismiss supplemental oxygen as a dyspnoea-relieving therapy in ILD, they should recognise that all studies reviewed by Bell et al. [1] were inadequately designed to evaluate the impact of supplemental oxygen on dyspnoea.

Disclosures

Supplementary Material

J.A. Guenette ERR-0033-2017_Guenette

C.J. Ryerson ERR-0033-2017_Ryerson

Footnotes

  • Support statement: M.R. Schaeffer was supported by a fellowship from the University of British Columbia. Y. Molgat-Seon was supported by a fellowship from the University of British Columbia and a postgraduate scholarship from the Natural Sciences and Engineering Research Council of Canada. C.J. Ryerson was supported by a Scholar Award from the Michael Smith Foundation for Health Research (MSFHR). J.A. Guenette was supported by a Scholar Award from the MSFHR and a Clinical Rehabilitation New Investigator Award from the Canadian Institutes of Health Research. The funders had no role in the preparation of this correspondence.

  • Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com

  • Provenance: Submitted article, peer reviewed.

  • Received March 26, 2017.
  • Accepted June 25, 2017.
  • Copyright ©ERS 2017.

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0

References

  1. ↵
    1. Bell EC,
    2. Cox NS,
    3. Goh N
    , et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017; 26: 160080.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Cao M,
    2. Wamboldt FS,
    3. Brown KK
    , et al. Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users. Multidiscip Respir Med 2015; 10: 37.
    OpenUrl
    1. Nishiyama O,
    2. Miyajima H,
    3. Fukai Y
    , et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med 2013; 107: 1241–1246.
    OpenUrlCrossRefPubMed
    1. Frank RC,
    2. Hicks S,
    3. Duck AM
    , et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012; 40: 269–270.
    OpenUrlFREE Full Text
  3. ↵
    1. Visca D,
    2. Montgomery A,
    3. de Lauretis A
    , et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011; 38: 987–990.
    OpenUrlFREE Full Text
  4. ↵
    1. Harris-Eze AO,
    2. Sridhar G,
    3. Clemens RE
    , et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150: 1616–1622.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Zechman FW,
    2. Wiley RL
    . Afferent inputs to breathing: respiratory sensation. Compr Physiol 2011; 1: Suppl. 11, 449–474.
    OpenUrl
  6. ↵
    1. Parshall MB,
    2. Schwartzstein RM,
    3. Adams L
    , et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Puente-Maestu L,
    2. Palange P,
    3. Casaburi R
    , et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016; 47: 429–460.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Dowman LM,
    2. McDonald CF,
    3. Bozinovski S
    , et al. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 2017; 22: 957–964.
    OpenUrl
  9. ↵
    1. Markovitz GH,
    2. Colthurst J,
    3. Storer TW
    , et al. Effective inspired oxygen concentration measured via transtracheal and oral gas analysis. Respir Care 2010; 55: 453–459.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Maggiore SM,
    2. Idone FA,
    3. Vaschetto R
    , et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med 2014; 190: 282–288.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Schaeffer MR,
    2. Ryerson CJ,
    3. Ramsook AH
    , et al. Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. Eur Respir J 2017; 49: 1602494.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ries AL
    . Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105–110.
    OpenUrlCrossRef
  13. ↵
    1. Ryerson CJ,
    2. Camp PG,
    3. Eves ND
    , et al. High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. Methodology of the HOPE-IPF study. Ann Am Thorac Soc 2016; 13: 1640–1647.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 26 Issue 145 Table of Contents
European Respiratory Review: 26 (145)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence
Michele R. Schaeffer, Yannick Molgat-Seon, Christopher J. Ryerson, Jordan A. Guenette
European Respiratory Review Sep 2017, 26 (145) 170033; DOI: 10.1183/16000617.0033-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence
Michele R. Schaeffer, Yannick Molgat-Seon, Christopher J. Ryerson, Jordan A. Guenette
European Respiratory Review Sep 2017, 26 (145) 170033; DOI: 10.1183/16000617.0033-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Supplemental oxygen and dypsnoea in ILD
Show more Agora

Correspondence

  • Supplemental oxygen and dypsnoea in ILD
  • Hypoxaemia in COVID-19: many pieces to a complex puzzle
  • V′A/Q′ mismatch is not the sole reason for hypoxaemia in early COVID-19
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2022 by the European Respiratory Society